Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis.


Journal

JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530

Informations de publication

Date de publication:
01 11 2020
Historique:
pubmed: 17 9 2020
medline: 19 5 2021
entrez: 16 9 2020
Statut: ppublish

Résumé

Although palmoplantar pustulosis (PPP) can significantly impact quality of life, the factors underlying disease severity have not been studied. To examine the factors associated with PPP severity. An observational, cross-sectional study of 2 cohorts was conducted. A UK data set including 203 patients was obtained through the Anakinra in Pustular Psoriasis, Response in a Controlled Trial (2016-2019) and its sister research study Pustular Psoriasis, Elucidating Underlying Mechanisms (2016-2020). A Northern European cohort including 193 patients was independently ascertained by the European Rare and Severe Psoriasis Expert Network (2014-2017). Patients had been recruited in secondary or tertiary dermatology referral centers. All patients were of European descent. The PPP diagnosis was established by dermatologists, based on clinical examination and/or published consensus criteria. The present study was conducted from October 1, 2014, to March 15, 2020. Demographic characteristics, comorbidities, smoking status, Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI), measuring severity from 0 (no sign of disease) to 72 (very severe disease), or Physician Global Assessment (PGA), measuring severity as 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe). Among the 203 UK patients (43 men [21%], 160 women [79%]; median age at onset, 48 [interquartile range (IQR), 38-59] years), the PPPASI was inversely correlated with age of onset (r = -0.18, P = .01). Similarly, in the 159 Northern European patients who were eligible for inclusion in this analysis (25 men [16%], 134 women [84%]; median age at onset, 45 [IQR, 34-53.3] years), the median age at onset was lower in individuals with a moderate to severe PGA score (41 years [IQR, 30.5-52 years]) compared with those with a clear to mild PGA score (46.5 years [IQR, 35-55 years]) (P = .04). In the UK sample, the median PPPASI score was higher in women (9.6 [IQR, 3.0-16.2]) vs men (4.0 [IQR, 1.0-11.7]) (P = .01). Likewise, moderate to severe PPP was more prevalent among Northern European women (57 of 134 [43%]) compared with men (5 of 25 [20%]) (P = .03). In the UK cohort, the median PPPASI score was increased in current smokers (10.7 [IQR, 4.2-17.5]) compared with former smokers (7 [IQR, 2.0-14.4]) and nonsmokers (2.2 [IQR, 1-6]) (P = .003). Comparable differences were observed in the Northern European data set, as the prevalence of moderate to severe PPP was higher in former and current smokers (51 of 130 [39%]) compared with nonsmokers (6 of 24 [25%]) (P = .14). The findings of this study suggest that PPP severity is associated with early-onset disease, female sex, and smoking status. Thus, smoking cessation intervention might be beneficial.

Identifiants

pubmed: 32936291
pii: 2770779
doi: 10.1001/jamadermatol.2020.3275
pmc: PMC7495329
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1216-1222

Subventions

Organisme : Department of Health
ID : 13/50/17
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S003126/1
Pays : United Kingdom

Auteurs

Natashia Benzian-Olsson (N)

Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.

Nick Dand (N)

Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.
Health Data Research UK, London, United Kingdom.

Charlotte Chaloner (C)

Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.

Zsuzsa Bata-Csorgo (Z)

Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.

Riccardo Borroni (R)

Humanitas Clinical and Research Center, IRCCS, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.

A David Burden (AD)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.

Hywel L Cooper (HL)

Portsmouth Dermatology Unit, Portsmouth Hospitals Trust, Portsmouth, United Kingdom.

Victoria Cornelius (V)

Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, United Kingdom.

Suzie Cro (S)

Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, United Kingdom.

Tejus Dasandi (T)

St John's Institute of Dermatology, King's College London, London, United Kingdom.

Christopher E M Griffiths (CEM)

Dermatology Centre, National Institute for Health Research Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom.

Külli Kingo (K)

Dermatology Clinic, Tartu University Hospital, Department of Dermatology, University of Tartu, Tartu, Estonia.

Sulev Koks (S)

Centre for Molecular Medicine and Innovative Therapeutics, Murdoch and Perron Institute for Neurological and Translational Science, Murdoch University, Nedlands, Western Australia, Australia.

Helen Lachmann (H)

National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom.

Helen McAteer (H)

The Psoriasis Association, Northampton, United Kingdom.

Freya Meynell (F)

St John's Institute of Dermatology, King's College London, London, United Kingdom.

Ulrich Mrowietz (U)

Psoriasis Center at the Department of Dermatology, University Medical Center, Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Richard Parslew (R)

Department of Dermatology, Royal Liverpool Hospitals, Liverpool, United Kingdom.

Prakash Patel (P)

St John's Institute of Dermatology, King's College London, London, United Kingdom.

Andrew E Pink (AE)

St John's Institute of Dermatology, King's College London, London, United Kingdom.

Nick J Reynolds (NJ)

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Department of Dermatology and National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

Adrian Tanew (A)

Department of Dermatology, Medical University of Vienna, Austria.

Kaspar Torz (K)

Psoriasis Center at the Department of Dermatology, University Medical Center, Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Hannes Trattner (H)

Department of Dermatology, Medical University of Vienna, Austria.

Shyamal Wahie (S)

Department of Dermatology, University Hospital of North Durham, Durham.

Richard B Warren (RB)

The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.

Andrew Wright (A)

Department of Dermatology, St Lukes Hospital, Bradford, United Kingdom.

Jonathan N Barker (JN)

St John's Institute of Dermatology, King's College London, London, United Kingdom.

Alexander A Navarini (AA)

Department of Dermatology & Allergy, University Hospital of Basel, Basel, Switzerland.

Catherine H Smith (CH)

St John's Institute of Dermatology, King's College London, London, United Kingdom.

Francesca Capon (F)

Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH